



[www.genfit.com](http://www.genfit.com)

## GENFIT TO PARTICIPATE AT MIDCAP EVENT ON SEPTEMBER 22-23, 2011

**Lille (France), Cambridge (Massachusetts, United States), September 16, 2011** – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces its participation to Midcap Event taking place at Palais Brongniart, Paris, on September 22<sup>th</sup> & 23<sup>rd</sup>, 2011.

During the event dedicated to meetings with the Financial community, Jean-François Mouney, CEO, and Laurent Lannoo, Corporate Secretary, will outline the Company strategy and perspectives following the positive results of its recent clinical trials, including the GFT505, as well as the strengthening of its financial structure established during Summer time.

GENFIT will be hosted at the CM-CIC Securities stand.

### **About GENFIT:**

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies (SANOFI, SERVIER, ...), to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase II.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 100 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). [www.genfit.com](http://www.genfit.com)

### **Contacts:**

#### **GENFIT**

Jean-François Mouney – CEO & Chairman of the Management Board  
+33 (0)3 2016 4000

#### **MILESTONES – Press Relations**

Bruno Arabian  
+33 (0)1 75 44 87 40 / +33 (0)6 87 88 47 26 – [barabian@milestones.fr](mailto:barabian@milestones.fr)